Gerresheimer Faces Liquidity Crisis and Potential SDAX Delisting

Pharma packager Gerresheimer misses financial filing deadline, triggering technical default. BaFin expands audit, forcing asset sales and risking SDAX delisting as shares plummet 70%.

The pharmaceutical packaging specialist Gerresheimer finds itself navigating a deepening corporate crisis. The company is now in technical default on its financing agreements after missing the deadline to file its audited annual financial statements. Management is preparing to take drastic action, including the sale of profitable U.S. operations, to avert an acute liquidity shortfall.

Regulatory Scrutiny and Index Consequences

Complicating the rescue effort is an expanded audit by the German Federal Financial Supervisory Authority (BaFin). The regulators are now specifically examining several balance sheet items beyond the previously known issues with "bill-and-hold" revenues. The areas under review include:
* Potential errors in lease liabilities (€65.5 million)
* Capitalized development costs and their useful lives (€29.4 million)
* Potentially delayed impairment charges in the Advanced Technologies segment (€196.5 million)

Due to these delays, the company has postponed its annual general meeting and quarterly financial reports indefinitely. The audited annual statement is now targeted for June 2026. This breach of Deutsche Börse's regulations is expected to lead to the stock's removal from the SDAX index.

Race to Secure Financing

The critical date of March 31 passed without Gerresheimer being able to present its certified figures. This formal covenant breach theoretically entitles lenders to terminate existing credit facilities immediately. The group is currently engaged in intensive negotiations with its financing banks to obtain waivers. Without these concessions, the funding for ongoing operations remains on unstable ground.

To alleviate the severe financial pressure, the company has mandated the investment bank Morgan Stanley to oversee the sale of its U.S. subsidiary, Centor Inc. Concurrently, Gerresheimer will close its Chicago Heights glass plant by the end of 2026, shifting production to facilities in Italy and India. The immense strain is reflected in the equity's market performance: with a recent closing price of €18.75, the share has lost nearly 70% of its value over the past twelve months.

While management formally maintains its operational targets for 2026, it explicitly ties their achievement to successful bank negotiations and a favorable outcome of the BaFin investigation. Until lenders sign binding waivers and regulators provide final clarity on the true state of the balance sheet, the corporation is operating without a reliable financial foundation.